[1]Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Adiministration Practice Guidelines Development Taskforce of the College of American Pathologists. JAMA, 1994, 271(10):777-781.
[2]Wade CE, Dubick MA, Blackbourne LH, et al. It is time to assess the utility of thrombelastography in the administration of blood products to the patient with traumatic injuries. J Trauma, 2009, 66(4):1258.
[3]Takahashi H, Urano T, Takada Y, et al. Fibrinolytic parameters as an admission prognostic marker of head injury in patients who talk and deteriorate. J Neurosurg, 1997, 86(5):768-772.
[4]Hoyt DB, Dutton RP, Hauser CJ, et al. Management of coagulopathy in the patients with multiple injuries: results from an international survey of clinical practice. J Trauma, 2008, 65(4):755-764.
[5]Lier H, Bttiger BW, Hinkelbein J, et al. Coagulation management in multiple trauma:a systematic review. Intensive Care Med, 2011, 37(4):572-582.
[6]Cotton BA, Au BK, Nunez TC, et al. Predefined massive transfusion protocols are associated with a reduction in organ failure and postinjury complications. J Trauma, 2009, 66(1):41-48.
[7]O’Keeffe T, Refaai M, Tchorz K, et al. A massive transfusion protocol to decrease blood component use and costs. Arch Surg, 2008, 143(7):686-690.
[8]Bechtel BF, Nunez TC, Lyon JA, et al. Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: a structured literature review. Int J Emerg Med, 2011, 4(1):40.
[9]Goldstein JN, Rosand J, Schwamm LH. Warfarin reversal in anticoagulant-associated intracerebral hemorrhage. Neurocrit Care, 2008, 9(2):277-283.
[10]Dutton RP, Mackenzie CF, Scalea TM. Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. J Trauma, 2002, 52(6):1141-1146.
[11]Rossaint R, Cerny V, Coats TJ, et al. Key issues in advanced bleeding care in trauma. Shock, 2006, 26(4):322-331.
[12]Kiraly LN, Differding JA, Enomoto TM, et al. Resuscitation with normal saline (NS) vs. lactated ringers (LR) modulates hypercoagulability and leads to increased blood loss in an uncontrolled hemorrhagic shock swine model. J Trauma, 2006, 61(1):57-64.
[13]D’Angelo MR, Dutton RP. Management of trauma-induced coagulopathy: trends and practices. AANA J, 2010, 78(1):35-40.
[14]Wilder DM, Reid TJ, Bakaltcheva IB. Hypertonic resuscitation and blood coagulation: in vitro comparison of several hypertonic solutions for their action on platelets and plasma coagulation. Thromb Res, 2002, 107(5):255-261.
[15]Martini WZ, Dubick MA, Wade CE, et al. Evaluation of trishydroxymethylaminomethane on reversing coagulation abnormalities caused by acidosis in pigs. Crit Care Med, 2007, 35(6):1568-1574.
[16]Eastridge BJ, Jenkins D, Flaherty S, et al. Trauma system development in a theater of war: Experiences from Operation Iraqi Freedom and Operation Enduring Freedom. J Trauma, 2006, 61(6):1366-1372.
[17]Spahn DR, Cerny V, Coats TJ, et al. Management of bleeding following major trauma: a European guideline. Crit Care, 2007, 11(1):R17.
[18]Bolliger D, Grlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology, 2010, 113(5):1205-1219.
[19]Blajchman MA, Bordin JO, Bardossy L, et al. The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. Br J Haematol, 1994, 86(2):347-350.
[20]Riskin DJ, Tsai TC, Riskin L, et al. Massive transfusion protocols: the role of aggressive resuscitation versus product ratio in mortality reduction. J Am Coll Surg, 2009, 209(2):198-205.
[21]Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg, 2008, 248(3):447-458.
[22]Meng ZH, Wolberg AS, Monroe DM 3rd, et al. The effect of temperature and pH on the activity of factor Ⅶa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma, 2003, 55(5):886-891.
[23]MacLaren R, Weber LA, Brake H, et al. A multicenter assessment of recombinant factor Ⅶa off-label usage: clinical experiences and associated outcomes. Transfusion, 2005, 45(9):1434-1442.
[24]Stein DM, Dutton RP, Kramer ME, et al. Recombinant factor Ⅶa:decreasing time to intervention in coagulopathic patients with severe traumatic brain injury. J Trauma, 2008, 64(3):620-627.
[25]Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma, 2005, 59(1):8-15.
[26]Brown CV, Foulkrod KH, Lopez D, et al. Recombinant factor Ⅶa for the correction of coagulopathy before emergent craniotomy in blunt trauma patients. J Trauma, 2010, 68(2):348-352.
[27]Stein DM, Dutton RP, Kramer ME, et al. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor Ⅶa is more cost-effective than plasma. J Trauma, 2009, 66(1):63-72.